AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
16 avr. 2024 08h03 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08 mars 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
05 mars 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...
ONWARD verstärkt Führungsteam auf Schlüsselpositionen in den Bereichen Clinical & Regulatory sowie Marketing
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, Niederlande, LAUSANNE, Schweiz und BOSTON, MA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Das Medizintechnikunternehmen ONWARD Medical N.V. (Euronext: ONWD), das innovative Therapien zur...
ONWARD renforce son management avec des nominations clés dans le domaine clinique et réglementaire et en marketing
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, Pays-Bas, LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, 06 nov. 2023 (GLOBE NEWSWIRE) -- ONWARD Medical SA (Euronext: ONWD), société de technologie médicale créant des thérapies innovantes...
ONWARD versterkt management met kernfuncties in Klinische & Regelgevende en Marketingafdelingen
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, Nederland, LAUSANNE, Zwitserland & BOSTON, MA, VS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve therapieën...
Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease
06 nov. 2023 12h13 HE
|
ONWARD Medical NV
EINDHOVEN, the Netherlands, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore...
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
03 nov. 2023 07h00 HE
|
AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
27 oct. 2023 07h00 HE
|
AC Immune SA
PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the...
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
05 sept. 2023 07h00 HE
|
AC Immune SA
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage...